Innovating to improve health worldwide

WIPO Committee on IP and Development (CDIP 35): Technology Transfer

On 20 November 2025, IFPMA submitted a statement on technology transfer at the WIPO Committee on IP and Development (CDIP 35) in Geneva. Technology transfer in the pharmaceutical sector is a complex and resource-intensive process. It requires significant technical expertise, time, and investment, as well as a robust, stable, and predictable intellectual property framework, which...

Biopharmaceutical CEOs Roundtable met in Berlin

12 NOVEMBER 2025, Berlin – The Biopharmaceutical CEOs Roundtable (BCR), a global policy platform representing the world’s leading biopharmaceutical companies, convened last week in Berlin to discuss how pharmaceutical innovation can drive better health outcomes, strengthen economies, and enhance global health security. The BCR delegation also met with Federal Chancellor Merz, along with key members...

WIPO Standing Committee on Patents (SCP 37): Technology Transfer

On 5 November 2025, IFPMA delivered a statement on technology transfer at the WIPO Standing Committee on Patents (SCP 37) in Geneva. Technology transfer in the pharmaceutical sector is a complex and resource-intensive process. It requires significant technical expertise, time, and investment, as well as a robust, stable, and predictable intellectual property framework, which is...

WIPO Standing Committee on Patents (SCP 37): Patents and health

On 4 November 2025, IFPMA delivered a statement on patents and health at the WIPO Standing Committee on Patents (SCP 37) in Geneva. The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) represents the global research-based biopharmaceutical industry. We appreciate the opportunity to address the Committee on patents and health. Intellectual property is fundamental to...